[1] |
LOKE J, BUKA R, CRADDOCK C. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?[J]. Front Immunol, 2021, 12: 659595. DOI: 10.3389/fimmu.2021.659595.
|
[2] |
XUAN L, LIU Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. J Hematol Oncol, 2021, 14(1): 4. DOI: 10.1186/s13045-020-01017-7.
|
[3] |
BEJANYAN N, WEISDORF DJ, LOGAN BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study[J]. Biol Blood Marrow Transplant, 2015, 21(3): 454-459. DOI: 10.1016/j.bbmt.2014.11.007.
|
[4] |
YANADA M, KONUMA T, YAMASAKI S, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes[J]. Bone Marrow Transplant, 2021, 56(5): 1126-1133. DOI: 10.1038/s41409-020-01163-z.
|
[5] |
KATO K. Treatment approach for relapse of adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation[J]. Rinsho Ketsueki, 2021, 62(5): 505-511. DOI: 10.11406/rinketsu.62.505.
|
[6] |
KUNADT D, STÖLZEL F. Effective immunosurveillance after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia[J]. Cancer Manag Res, 2021, 13: 7411-7427. DOI: 10.2147/CMAR.S261721.
|
[7] |
KREIDIEH F, ABOU DALLE I, MOUKALLED N, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment[J]. Int J Hematol, 2022, 116(3): 330-340. DOI: 10.1007/s12185-022-03416-7.
|
[8] |
AITKEN MJL, RAVANDI F, PATEL KP, et al. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia[J]. J Hematol Oncol, 2021, 14(1): 137. DOI: 10.1186/s13045-021-01148-5.
|
[9] |
MAFFINI E, LABOPIN M, BEELEN DW, et al. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)[J]. Bone Marrow Transplant, 2022, 57(10): 1556-1563. DOI: 10.1038/s41409-022-01748-w.
|
[10] |
VONK CM, AL HINAI ASA, HANEKAMP D, et al. Molecular minimal residual disease detection in acute myeloid leukemia[J]. Cancers (Basel), 2021, 13(21): 5431. DOI: 10.3390/cancers13215431.
|
[11] |
张静, 王宗慧. 白血病与淋巴瘤的微小残留病检测手段前景及临床意义探讨[J]. 现代肿瘤医学, 2022, 30(21): 4009-4013. DOI: 10.3969/j.issn.1672-4992.2022.21.037.ZHANG J, WANG ZH. Prospects and clinical significance of detection methods for minimal residual disease in the field of leukemia and lymphoma[J]. J Mod Oncol, 2022, 30(21): 4009-4013. DOI: 10.3969/j.issn.1672-4992.2022.21.037.
|
[12] |
DÖHNER H, ESTEY E, GRIMWADE D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. DOI: 10.1182/blood-2016-08-733196.
|
[13] |
IVEY A, HILLS RK, SIMPSON MA, et al. Assessment of minimal residual disease in standard-risk AML[J]. N Engl J Med, 2016, 374(5): 422-433. DOI: 10.1056/NEJMoa1507471.
|
[14] |
ALI N, TOMLINSON B, PATEL RD, et al. Role of post-allogeneic hematopoietic stem cell transplantation low-dose azacitidine for prevention of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome: a retrospective analysis[J]. Biol Blood Marrow Transplant, 2020, 26(3): S126-S127. DOI: 10.1016/j.bbmt.2019.12.643.
|
[15] |
PLATZBECKER U, MIDDEKE JM, SOCKEL K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2018, 19(12): 1668-1679. DOI: 10.1016/S1470-2045(18)30580-1.
|
[16] |
GUILLAUME T, MALARD F, MAGRO L, et al. Prospective phase Ⅱ study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome[J]. Bone Marrow Transplant, 2019, 54(11): 1815-1826. DOI: 10.1038/s41409-019-0536-y.
|
[17] |
LIBERATORE C, STANGHELLINI MTL, LORENTINO F, et al. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors[J]. Ther Adv Hematol, 2022, 13: 20406207221090882. DOI: 10.1177/20406207221090882.
|
[18] |
GUO WW, SU XH, WANG MY, et al. Regulatory T cells in GVHD therapy[J]. Front Immunol, 2021, 12: 697854. DOI: 10.3389/fimmu.2021.697854.
|
[19] |
GROVER P, GOEL PN, GREENE MI. Regulatory T cells: regulation of identity and function[J]. Front Immunol, 2021, 12: 750542. DOI: 10.3389/fimmu.2021.750542.
|
[20] |
GOODYEAR OC, DENNIS M, JILANI NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)[J]. Blood, 2012, 119(14): 3361-3369. DOI: 10.1182/blood-2011-09-377044.
|
[21] |
GAO L, ZHANG Y, WANG S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial[J]. J Clin Oncol, 2020, 38(36): 4249-4259. DOI: 10.1200/JCO.19.03277.
|
[22] |
ROMAN-GOMEZ J, JIMENEZ-VELASCO A, CASTILLEJO JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia[J]. Blood, 2004, 104(8): 2492-2498. DOI: 10.1182/blood-2004-03-0954.
|
[23] |
刘佳. 小剂量地西他滨联合丙戊酸用于急性白血病/骨髓增生异常综合征异基因造血干细胞移植后维持治疗[D]. 郑州: 郑州大学, 2019.
|
[24] |
WU M, LI C, ZHU X. FLT3 inhibitors in acute myeloid leukemia[J]. J Hematol Oncol, 2018, 11(1): 133. DOI: 10.1186/s13045-018-0675-4.
|
[25] |
HUANG Y, HU J, LU T, et al. Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis[J]. Cancer Manag Res, 2019, 11: 4129-4142. DOI: 10.2147/CMAR.S194523.
|
[26] |
ANTAR AI, OTROCK ZK, JABBOUR E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions[J]. Leukemia, 2020, 34(3): 682-696. DOI: 10.1038/s41375-019-0694-3.
|
[27] |
XUAN L, WANG Y, HUANG F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial[J]. Lancet Oncol, 2020, 21(9): 1201-1212. DOI: 10.1016/S1470-2045(20)30455-1.
|
[28] |
BURCHERT A, BUG G, FRITZ LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)[J]. J Clin Oncol, 2020, 38(26): 2993-3002. DOI: 10.1200/JCO.19.03345.
|
[29] |
SANDMAIER BM, KHALED S, ORAN B, et al. Results of a phase 1 study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell transplantation[J]. Blood, 2014, 124(21): 428. DOI: 10.1182/blood.v124.21.428.428.
|
[30] |
DUCHMANN M, MICOL JB, DUPLOYEZ N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study[J]. Blood, 2021, 137(20): 2827-2837. DOI: 10.1182/blood.2020010165.
|
[31] |
DINARDO CD, STEIN EM, DE BOTTON S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398. DOI: 10.1056/NEJMoa1716984.
|
[32] |
STEIN EM, DINARDO CD, POLLYEA DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J]. Blood, 2017, 130(6): 722-731. DOI: 10.1182/blood-2017-04-779405.
|
[33] |
刘艺, 裴仁治. Bcl-2抑制剂维奈托克在较高危组骨髓增生异常综合征中的治疗进展[J]. 实用医学杂志, 2022, 38(16): 2106-2109. DOI: 10.3969/j.issn.1006-5725.2022.16.023.LIU Y, PEI RZ. Advances of Bcl-2 inhibitor venetoclaxfor higher-risk groups of myelodysplastic syndromes[J]. J Pract Med, 2022, 38(16): 2106-2109. DOI: 10.3969/j.issn.1006-5725.2022.16.023.
|
[34] |
ZHAO P, NI M, MA D, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2022, 101(1): 119-130. DOI: 10.1007/s00277-021-04674-x.
|
[35] |
SERPENTI F, SCIUMÈ M, GALASSI G, et al. Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse[J]. Leuk Lymphoma, 2022, 63(11): 2743-2746. DOI: 10.1080/10428194.2022.2090553.
|
[36] |
WEI Y, XIONG X, LI X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome[J]. Cancer Sci, 2021, 112(9): 3636-3644. DOI: 10.1111/cas.15048.
|
[37] |
KENT A, POLLYEA DA, WINTERS A, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse[J]. Blood, 2020, 136(Suppl 1): 11-12. DOI: 10.1182/blood-2020-138832.
|
[38] |
KENT A, VASU S, SCHATZ D, et al. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse[J]. Blood Adv, 2020, 4(13): 3102-3108. DOI: 10.1182/bloodadvances.2020001991.
|
[39] |
HARADA K, MIZUNO S, YANO S, et al. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia[J]. Ann Hematol, 2022, 101(3): 643-653. DOI: 10.1007/s00277-021-04731-5.
|
[40] |
YAN CH, LIU QF, WU DP, et al. Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple dlis could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia[J]. Biol Blood Marrow Transplant, 2017, 23(8): 1311-1319. DOI: 10.1016/j.bbmt.2017.04.028.
|
[41] |
LULLA PD, NAIK S, VASILEIOU S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant[J]. Blood, 2021, 137(19): 2585-2597. DOI: 10.1182/blood.2020009471.
|
[42] |
GUILLAUME T, THÉPOT S, PETERLIN P, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome[J]. Transplant Cell Ther, 2021, 27(10): 839. e1-839. e6. DOI: 10.1016/j.jtct.2021.06.029.
|
[43] |
SHEN X, PAN J, QI C, et al. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of allogeneic hematopoietic stem cell transplantation for acute leukemia[J]. Hematology, 2021, 26(1): 295-300. DOI: 10.1080/16078454.2021.1889162.
|